The Effect of Dapagliflozin Combined with Sacubitril Valsartan Sodium on the Treatment of Patients with Chronic Heart Failure and Diabetes Mellitus

Abstract Background Chronic heart failure (CHF) refers to a cardiovascular disease where the heart's pumping function is impaired, making it unable to meet the metabolic demands of the body's tissues. Diabetes (DM) is prone to causing changes in myocardial metabolism, resulting in long-term elevated blood glucose levels, increased inflammatory factors, disruption of vascular endothelial function, and aggravation of microcirculation disorders. The mutual influence between CHF and DM can lead to a vicious cycle and increase the difficulty of treatment. Purpose This study was designed to study the effect of dapagliflozin combined with sacubitril valsartan sodium on the treatment of patients with CHF and DM. Methods A total of 80 patients with CHF and DM were selected as the subjects, were randomly divided into the observation group and control group(n=40). The control group received conventional treatment in combination with sacubitril and valsartan sodium, while the observation group received additional treatment with dapagliflozin on top of the control group. After 3 months of treatment, the efficacy, cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI)], blood glucose indicators [average 24-hour blood glucose absolute difference (MODD), average blood glucose fluctuation range (MAGE), maximum blood glucose fluctuation range (LAGE)], and incidence of adverse reactions were compared between the two groups. Results After treatment, the total effective rate of the observation group was higher than the control group. After treatment, the LVEF levels in both groups were higher, while the LVESVI and LVEDVI levels were lower than before treatment. The LVEF in the observation group was higher, while LVEDVI and LVESVI were lower than those in the control group. After treatment, the levels of LAGE, MAGE, and MODD in both groups were lower than before treatment, and the observation group had lower levels of LAGE, MAGE, and MODD. There was no difference in the total incidence of adverse reactions between the two groups. Conclusion The clinical effect of dapagliflozin combined with sacubitril valsartan sodium in the treatment of CHF and DM patients is significant, which can improve patients' cardiac function, control blood glucose, and the safety is worthy of recognition.